246 related articles for article (PubMed ID: 26697766)
1. De-intensifying treatment in established rheumatoid arthritis (RA): Why, how, when and in whom can DMARDs be tapered?
Fautrel B; Den Broeder AA
Best Pract Res Clin Rheumatol; 2015; 29(4-5):550-65. PubMed ID: 26697766
[TBL] [Abstract][Full Text] [Related]
2. Therapeutic strategy for rheumatoid arthritis patients who have achieved remission.
Fautrel B
Joint Bone Spine; 2018 Dec; 85(6):679-685. PubMed ID: 29452300
[TBL] [Abstract][Full Text] [Related]
3. Impact of flare on radiographic progression after etanercept continuation, tapering or withdrawal in patients with rheumatoid arthritis.
Smolen JS; Pedersen R; Jones H; Mahgoub E; Marshall L
Rheumatology (Oxford); 2020 Jan; 59(1):153-164. PubMed ID: 31257453
[TBL] [Abstract][Full Text] [Related]
4. [Discontinuation or tapering strategies of biologics in rheumatoid arthritis in remission].
Mallick A; Fautrel B; Sagez F; Sordet C; Javier RM; Petit H; Chatelus E; Rahal N; Gottenberg JE; Sibilia J
Rev Med Interne; 2017 Apr; 38(4):256-263. PubMed ID: 28161110
[TBL] [Abstract][Full Text] [Related]
5. Effects of tapering conventional synthetic disease-modifying antirheumatic drugs to drug-free remission versus stable treatment in rheumatoid arthritis (ARCTIC REWIND): 3-year results from an open-label, randomised controlled, non-inferiority trial.
Kjørholt KE; Sundlisæter NP; Aga AB; Sexton J; Olsen IC; Fremstad H; Spada C; Madland TM; Høili CA; Bakland G; Lexberg Å; Hansen IJW; Hansen IM; Haukeland H; Ljoså MA; Moholt E; Uhlig T; Kvien TK; Solomon DH; van der Heijde D; Haavardsholm EA; Lillegraven S
Lancet Rheumatol; 2024 May; 6(5):e268-e278. PubMed ID: 38583450
[TBL] [Abstract][Full Text] [Related]
6. Risk of losing remission, low disease activity or radiographic progression in case of bDMARD discontinuation or tapering in rheumatoid arthritis: systematic analysis of the literature and meta-analysis.
Henaux S; Ruyssen-Witrand A; Cantagrel A; Barnetche T; Fautrel B; Filippi N; Lukas C; Raffeiner B; Rossini M; Degboé Y; Constantin A
Ann Rheum Dis; 2018 Apr; 77(4):515-522. PubMed ID: 29187350
[TBL] [Abstract][Full Text] [Related]
7. Relapse rates in patients with rheumatoid arthritis in stable remission tapering or stopping antirheumatic therapy: interim results from the prospective randomised controlled RETRO study.
Haschka J; Englbrecht M; Hueber AJ; Manger B; Kleyer A; Reiser M; Finzel S; Tony HP; Kleinert S; Feuchtenberger M; Fleck M; Manger K; Ochs W; Schmitt-Haendle M; Wendler J; Schuch F; Ronneberger M; Lorenz HM; Nuesslein H; Alten R; Demary W; Henes J; Schett G; Rech J
Ann Rheum Dis; 2016 Jan; 75(1):45-51. PubMed ID: 25660991
[TBL] [Abstract][Full Text] [Related]
8. Flare Rate in Patients with Rheumatoid Arthritis in Low Disease Activity or Remission When Tapering or Stopping Synthetic or Biologic DMARD: A Systematic Review.
Kuijper TM; Lamers-Karnebeek FB; Jacobs JW; Hazes JM; Luime JJ
J Rheumatol; 2015 Nov; 42(11):2012-22. PubMed ID: 26428204
[TBL] [Abstract][Full Text] [Related]
9. Step-down strategy of spacing TNF-blocker injections for established rheumatoid arthritis in remission: results of the multicentre non-inferiority randomised open-label controlled trial (STRASS: Spacing of TNF-blocker injections in Rheumatoid ArthritiS Study).
Fautrel B; Pham T; Alfaiate T; Gandjbakhch F; Foltz V; Morel J; Dernis E; Gaudin P; Brocq O; Solau-Gervais E; Berthelot JM; Balblanc JC; Mariette X; Tubach F
Ann Rheum Dis; 2016 Jan; 75(1):59-67. PubMed ID: 26103979
[TBL] [Abstract][Full Text] [Related]
10. Tapering conventional synthetic DMARDs in patients with early arthritis in sustained remission: 2-year follow-up of the tREACH trial.
Kuijper TM; Luime JJ; de Jong PH; Gerards AH; van Zeben D; Tchetverikov I; de Sonnaville PB; van Krugten MV; Grillet BA; Hazes JM; Weel AE
Ann Rheum Dis; 2016 Dec; 75(12):2119-2123. PubMed ID: 27283332
[TBL] [Abstract][Full Text] [Related]
11. Design of a phase IV randomised, double-blind, placebo-controlled trial assessing the Im
Emery P; Burmester GR; Naredo E; Zhou Y; Hojnik M; Conaghan PG
BMJ Open; 2018 Feb; 8(2):e019007. PubMed ID: 29490959
[TBL] [Abstract][Full Text] [Related]
12. Cost-Effectiveness of TNF-Blocker Injection Spacing for Patients with Established Rheumatoid Arthritis in Remission: An Economic Evaluation from the Spacing of TNF-Blocker Injections in Rheumatoid Arthritis Trial.
Vanier A; Mariette X; Tubach F; Fautrel B;
Value Health; 2017 Apr; 20(4):577-585. PubMed ID: 28407999
[TBL] [Abstract][Full Text] [Related]
13. Can we discontinue synthetic disease-modifying anti-rheumatic drugs in rheumatoid arthritis?
Scott IC; Kingsley GH; Scott DL
Clin Exp Rheumatol; 2013; 31(4 Suppl 78):S4-8. PubMed ID: 24129128
[TBL] [Abstract][Full Text] [Related]
14. What are the dangers of biological therapy discontinuation or dose reduction strategies when treating rheumatoid arthritis?
Atzeni F; Benucci M; Talotta R; Masala IF; Sarzi-Puttini P; Govoni M
Expert Rev Clin Pharmacol; 2016 Nov; 9(11):1403-1411. PubMed ID: 27634311
[TBL] [Abstract][Full Text] [Related]
15. Tapering biologic and conventional DMARD therapy in rheumatoid arthritis: current evidence and future directions.
Schett G; Emery P; Tanaka Y; Burmester G; Pisetsky DS; Naredo E; Fautrel B; van Vollenhoven R
Ann Rheum Dis; 2016 Aug; 75(8):1428-37. PubMed ID: 27261493
[TBL] [Abstract][Full Text] [Related]
16. Dose tapering and discontinuation of biological therapy in rheumatoid arthritis patients in routine care - 2-year outcomes and predictors.
Brahe CH; Krabbe S; Østergaard M; Ørnbjerg L; Glinatsi D; Røgind H; Jensen HS; Hansen A; Nørregaard J; Jacobsen S; Terslev L; Huynh TK; Jensen DV; Manilo N; Asmussen K; Brown Frandsen P; Boesen M; Rastiemadabadi Z; Morsel Carlsen L; Møller JM; Krogh NS; Hetland ML
Rheumatology (Oxford); 2019 Jan; 58(1):110-119. PubMed ID: 30169706
[TBL] [Abstract][Full Text] [Related]
17. Circulating calprotectin (S100A8/A9) is higher in rheumatoid arthritis patients that relapse within 12 months of tapering anti-rheumatic drugs.
de Moel EC; Rech J; Mahler M; Roth J; Vogl T; Schouffoer A; Goekoop RJ; Huizinga TWJ; Allaart CF; Toes REM; Schett G; van der Woude D
Arthritis Res Ther; 2019 Dec; 21(1):268. PubMed ID: 31805992
[TBL] [Abstract][Full Text] [Related]
18. Tapering of biological antirheumatic drugs in rheumatoid arthritis patients is achievable and cost-effective in daily clinical practice: data from the Brussels UCLouvain RA Cohort.
Dierckx S; Sokolova T; Lauwerys BR; Avramovska A; de Bellefon LM; Toukap AN; Stoenoiu M; Houssiau FA; Durez P
Arthritis Res Ther; 2020 Apr; 22(1):96. PubMed ID: 32345367
[TBL] [Abstract][Full Text] [Related]
19. Low rates of biologic-free clinical disease activity index remission maintenance after biologic disease-modifying anti-rheumatic drug discontinuation while in remission in a Japanese multicentre rheumatoid arthritis registry.
Yoshida K; Kishimoto M; Radner H; Matsui K; Okada M; Saeki Y; Solomon DH; Tohma S
Rheumatology (Oxford); 2016 Feb; 55(2):286-90. PubMed ID: 26350484
[TBL] [Abstract][Full Text] [Related]
20. Relapse in rheumatoid arthritis patients undergoing dose reduction and withdrawal of biologics: are predictable factors more relevant than predictive parameters? An observational prospective real-life study.
Vittecoq O; Desouches S; Kozyreff M; Nicolau J; Pouplin S; Rottenberg P; Sens N; Lequerre T; Avenel G
BMJ Open; 2019 Dec; 9(12):e031467. PubMed ID: 31857303
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
